Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This clinical trial is conducted by one of 4 locations; University of British Columbia
(Vancouver, CA), University of Utah (Salt Lake City, UT, USA), University of Cincinnati
(Cincinnati, OH, USA), and University of Hamburg (Hamburg, Germany).
Adults with NF1 have a higher risk of osteopenia and osteoporosis, a condition of low bone
density that can lead to fragile bones and bone breakage.
People with NF1 also have lower vitamin D levels than unaffected individuals. Vitamin D is
important for normal bone health, but studies to improve bone health by vitamin D
supplementation in people with NF1 have not been tried.
The purpose of this study is to treat adults with NF1 who have insufficient serum vitamin D
levels with 2 different doses of vitamin D supplementation to determine if vitamin D
supplementation ameliorates the usual loss of bone mineral density over 2 years.
Phase:
Phase 2
Details
Lead Sponsor:
University of Utah
Collaborators:
Children's Hospital Medical Center, Cincinnati U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command Universitätsklinikum Hamburg-Eppendorf University of British Columbia
Treatments:
Cholecalciferol Ergocalciferols Vitamin D Vitamins